Interferon Beta-1A

證據等級: L5

預測適應症: 10 個

Interferon beta-1a: From Multiple Sclerosis to Jeune Syndrome Situs Inversus

One-Sentence Summary

Interferon beta-1a is an immunomodulatory biologic globally established for relapsing forms of multiple sclerosis. The TxGNN model predicts a possible link to Jeune syndrome situs inversus (a rare congenital ciliopathy/skeletal dysplasia) with a 97.47% prediction score, but this direction currently has zero clinical trials and zero publications supporting it, and the model’s own rationale flags the score as likely a knowledge-graph artefact rather than a genuine signal.

Quick Overview

Item	Content
Original Indication	Multiple Sclerosis (well-established global indication; not present in the supplied Danish regulatory dataset — see note below)
Predicted New Indication	Jeune syndrome situs inversus
TxGNN Prediction Score	97.47%
Evidence Level	L5
Denmark Market Status	Not marketed
Number of Marketing Authorisations	0
Recommended Decision	Hold

Note: taiwan_regulatory.licenses is empty for this evidence pack (product not currently authorised in Denmark), so the original indication above is drawn from the drug’s globally documented use — corroborated by the multiple-sclerosis literature present elsewhere in this evidence pack — rather than from Danish label text.

Why is This Prediction Reasonable?

Currently, detailed mechanism-of-action data is not available (flagged as a High-severity data gap, DG002). Based on known information, interferon beta-1a exerts antiviral and immunomodulatory effects via IFNAR signalling and modulation of Th1/Th17 responses, and its efficacy in relapsing multiple sclerosis is well established.

However, the model’s own repurposing rationale for this specific prediction is explicitly negative: Jeune syndrome (asphyxiating thoracic dystrophy) with situs inversus is a congenital ciliopathy and skeletal dysplasia — a structural/developmental disorder, not an immune or inflammatory condition. There is no known mechanistic overlap with interferon beta-1a’s antiviral/immunomodulatory pathway.

The evidence pack itself attributes the unusually high TxGNN score to a likely graph artefact: rare-disease nodes in the knowledge graph tend to have sparse connectivity, which can inflate similarity-based prediction scores without reflecting genuine biological plausibility. This prediction should therefore be treated as a hypothesis-generation output only, not as evidence of therapeutic potential.

Clinical Trial Evidence

Currently no related clinical trials registered

Literature Evidence

Currently no related literature available

Denmark Market Information

Interferon beta-1a does not currently hold any marketing authorisation in Denmark under this evidence pack (market status: Not marketed, 0 authorisations on file).

Safety Considerations

Please refer to the approved Summary of Product Characteristics (SmPC) for safety information. (Danish label warnings, contraindications, and drug-interaction data are recorded as a Blocking data gap, DG001, and were not available for this evaluation.)

Conclusion and Next Steps

Decision: Hold

Rationale: This prediction has no supporting clinical trials or literature, and the model’s own rationale identifies it as a probable false positive driven by sparse connectivity around a rare-disease node rather than a genuine mechanistic signal. Evidence Level L5 (model prediction only) does not support advancing this candidate.

To proceed, the following is needed:

Danish SmPC warnings/contraindications (DG001, Blocking) — required before any S1 safety screening can begin
Verified mechanism-of-action data (DG002, High) to properly assess biological plausibility
Independent re-scoring or manual review of this drug–disease pair, given the documented risk of noise in sparsely connected rare-disease knowledge-graph nodes
Any preclinical or mechanistic evidence connecting type-I interferon signalling to ciliopathy/skeletal dysplasia pathology, which is currently entirely absent
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.